# Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

> **NCT05969847** · PHASE2 · NOT_YET_RECRUITING · sponsor: **池畔** · enrollment: 72 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** split-course hypofraction radiotherapy
- **DRUG:** CAPOX
- **DRUG:** Envafolimab
- **PROCEDURE:** Local excision

## Key facts

- **NCT ID:** NCT05969847
- **Lead sponsor:** 池畔
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969847, "Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05969847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*